Eli Lilly (NYSE:LLY)
Chief Scientific Officer Daniel Skovronsky says the company has human
trials underway with two antibody therapies. If things go well in August
and September – with folks under treatment not having to move into
hospitalization – it could lead to emergency use authorization, he says.
“September, October, November is not unreasonable.”
Lilly also has a third antibody treatment under study that could soon move to human trials.
https://seekingalpha.com/news/3582085-lillys-covidminus-19-treatment-maybe-available-soon-september
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.